

Docket No. 3816-4000By FacsimileIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Peter Kufer, et al.

Group Art Unit: 1646

Serial No.: 09/403,107

Examiner: John F. Murphy, Ph.D.

Filed: October 14, 1999

For: NOVEL METHOD FOR THE PRODUCTION OF ANTIHUMAN ANTIGEN RECEPTORS AND USES THEREOF

AMENDMENT FEE TRANSMITTALCommissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

☒ No additional fee is required.☐ The additional fee has been calculated as shown below:CLAIMS AS AMENDED

| | Claims Remaining After Amendment | Highest No. Covered by Previous Payments | Extra | Rate | Additional Fee |
|---------------------------------|---|---|-------|---------------------|-------------------|
| Total Claims* | 47 - | 89 | 0 | \$18.00/ \$9.00 | \$ 0 |
| Independent Claims | 3 - | 3 | 0 | \$80.00/ \$40.00 | \$ 0 |
| Multiple Dependent Claims | (If claims added by amendment include Multiple Dependent Claim(s) and there was no Multiple Dependent Claim(s) in application before amendment add \$270.00 to additional fee (\$135 for small entity). | | | | \$ 0 |
| TOTAL | | | | | \$ 0 |

*Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. §1.75(c).

☐ Small entity status is or has been claimed.


Docket No. 3816-4000

Reduced Fees Under 37 C.F.R. §1.9(f) paid herewith \$. . . .

- ☐ Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for filing this amendment, including all fees pursuant to 37 CFR §1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3816-4000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☐ _____ Pages Sequence Listing
- ☐ _____ Computer disk(s) containing substitute Sequence Listing
- ☐ Statement under 37 C.F.R. §1.825(b) that the computer and paper copies of the substitute Sequence Listing are the same.
- ☐ A check in the amount of \$_____ to cover the filing fee is attached.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.Dated: November 27, 2001

By: _____


Maria C.H. Lin
Registration No. 29,323Correspondence Address:MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

| SERIAL NUMBER | FILING DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NO. |
|---------------|-------------|-----------------------|---------------------|
| | | | |

| EXAMINER | |
|----------|--------------|
| | |
| ART UNIT | PAPER NUMBER |
| | |

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN **30 days** FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. **In no case may an applicant extend the period for response beyond the six month statutory period.** Applicant is requested to return a copy of the attached Notice to Comply with the response.

Applicant please note that the Claims and Specification must be amended to include sequences by Sequence Identification Number (SEQ ID:NO._). Note particularly Claim 32 in which specific sequences are claimed absent-SEQ ID NOS:.

Any inquiry concerning this communication should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Christina Chan whose telephone number is (703) 308-3973.

G.R. Ewoldt, Ph.D.
Patent Examiner
Tech Center 1600
October 24, 2001

Patrick J. Nolan
Patrick J. Nolan, Ph.D.
Primary Examiner
Tech Center 1600

FAX RECEIVED

NOV 29 2001

GROUP BOX COVER SHEET

MORGAN & FINNEGAN, L.L.P.

A Registered Limited Liability Partnership
345 Park Avenue
New York, NY 10154-0053
Telephone: (212) 758-4800
Facsimile: (212) 751-6849

OFFICIAL

| To | COMPANY | FAX | PHONE |
|---------------------|---------|--------------|-------|
| Gerald Ewoldt, Ph.D | USPTO | 703-305-3014 | |

| | | | |
|-----------------|----------------|---------------------------------|-------------------|
| FROM: | Maria C.H. Lin | DATE: | November 27, 2001 |
| PHONE: | (212) 415-8745 | CLIENT/MATTER: | 3816-4000 |
| CONFIRM: | | PAGES (INCLUDING COVER): | 12 |

COMMENTS:

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAINS INFORMATION FROM THE LAW FIRM OF MORGAN & FINNEGAN L.L.P. WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ON THIS TRANSMISSION SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS FAXED INFORMATION IS STRICTLY PROHIBITED, AND THE DOCUMENT(S) SHOULD BE RETURNED TO THIS FIRM IMMEDIATELY. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US BY TELEPHONE IMMEDIATELY SO THAT WE CAN ARRANGE FOR THE RETURN OF THE ORIGINAL DOCUMENTS AT NO COST TO YOU.

PATENTDocket No. 3816-4000**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Peter Kufer, et al
Serial No : 09/403,107
Filed : October 14, 1999
For : NOVEL METHOD FOR THE PRODUCTION OF ANTIHUMAN
ANTIGEN RECEPTORS AND USES THEREOF
Group Art Unit : 1646
Examiner : Gerald Ewoldt, Ph.D.
Office Action : November 2, 2001

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION


Sir:

I hereby certify that the attached Amendment and Response and Amendment Fee Transmittal are being transmitted on the date shown below to Examiner Gerald Ewoldt, Ph.D of Group No. 1646 at the following facsimile number: 703-305-3014.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: November 27, 2001

By:


Maria C. H. Lin
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

PATENT
Docket No. 3816-4000
Facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peter Kufer, et al
Serial No : 09/403,107
Filed : October 14, 1999
For : NOVEL METHOD FOR THE PRODUCTION OF ANTIHUMAN
ANTIGEN RECEPTORS AND USES THEREOF
Group Art Unit : 1646
Examiner : Gerald Ewoldt, Ph.D.
Office Action : November 2, 2001

Commissioner for Patents
Washington, D.C. 20231

Attention: Non-Fee Amendment

AMENDMENT AND RESPONSE

Sir:

This is in response to the office action dated November 2, 2001 for which a shortened period of response of one month was set.

Please amend the above-identified application as follows:

IN THE CLAIMS:

The claims now pending are: 1-22, 26-29, 31-32, 34-52.

Please amend the claims 9, 10, 11, 13, 18, 22, 28, 31, 32 as follows:

9. The method according to claim 8, wherein said VH-chain is nucleotides 1 to 381 of SEQ ID NO: 143 and said VL chain is nucleotides 1 to 321 of SEQ ID NO: 141.

10. The method according to claim 9, wherein said selection steps comprise:

(-1-)

7¹
subg¹

7² [665767 v1]